# ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer

> **NCT00662597** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1285 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** ASA404
- **DRUG:** Placebo
- **DRUG:** carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00662597
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 1285 (ACTUAL)
- **Last updated:** 2020-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00662597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00662597, "ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00662597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*